T Cell News and Research

Latest T Cell News and Research

Medco announces new offerings within Advanced Oncology Solutions

Medco Health Solutions, Inc. today announced new offerings within its Advanced Oncology Solutions, that include treatment pathways decision support with embedded pharmacogenomic testing and nutrition recommendations for cancer patients.

20 Jul 2011

Chemotherapy combined with anti-cancer agent shows promise for treatment of aggressive breast cancers

Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown.

20 Jul 2011

Normal stem cell encourages growth of cancer stem cells and fuels ovarian cancer

Researchers at the University of Michigan Comprehensive Cancer Center have found that a type of normal stem cell fuels ovarian cancer by encouraging cancer stem cells to grow.

20 Jul 2011

Hallmark of cancer cells

Scientists from the Hebrew University have identified the molecular basis for DNA breakage, a hallmark of cancer cells. The findings of this research have just been published in the journal Molecular Cell.

20 Jul 2011

New technology for processing human waste in developing countries

The Bill & Melinda Gates Foundation has awarded Delft University of Technology, a grant to 'Reinvent the toilet'. Aim of this project is to develop new technology for processing human waste without links to water, energy, or sewer lines, and at costs affordable to the poor in developing countries.

20 Jul 2011

Possible new drug targets for treating diffuse large B-cell lymphoma

Researchers at the University of Maryland School of Medicine have discovered a novel interaction between two proteins involved in regulating cell growth that could provide possible new drug targets for treating diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma.

20 Jul 2011

New transgenic mouse could predict toxicity of targeted cancer drugs

Only one in twenty cancer drugs makes its way from the laboratory to become an approved pharmaceutical product. The majority of new agents are only shown to be unsuitable in the later phases of clinical development which would explain the exorbitantly high development costs of 500 to 600 million euros per new cancer drug.

20 Jul 2011

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the submission of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for VELCADE® (bortezomib) for injection to add overall survival data after a five-year follow up to the product label.

20 Jul 2011

Nuclear Factor I/B appears to drive progression of small cell lung cancer

A major challenge for cancer biologists is figuring out which among the hundreds of genetic mutations found in a cancer cell are most important for driving the cancer's spread.

20 Jul 2011

Gel Company, Biomerix partner to market and distribute 3D Scaffold

Biomerix Corporation and Gel Company today announced a strategic distribution agreement for the Biomerix 3D Scaffold, a novel three-dimensional tissue scaffold. Under the agreement, Gel Company will market and distribute the Biomerix 3D Scaffold to researchers in the life science community across the United States.

20 Jul 2011

Two key genes may help prevent childhood leukemia

Researchers at The University of Western Ontario have identified genes that may be important for preventing childhood leukemia. Acute lymphoblastic leukemia (ALL) is a cancer of the blood that occurs primarily in young children.

19 Jul 2011

Sigma introduces CompoZr Targeted Integration Kit – mRosa26

Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich Corporation today announced the launch of CompoZr Targeted Integration Kit – mRosa26, which can precisely and rapidly integrate transgenes into the mouse genome at the Rosa26 safe harbor locus.

19 Jul 2011

EPA to expand Cooperative Research And Development Agreement with NanoLogix

NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today the U.S. Environmental Protection Agency (EPA) intends to expand its Cooperative Research And Development Agreement (CRADA) with NanoLogix to include additional water-borne pathogens.

19 Jul 2011

Natural formula can fight against highly invasive breast cancer

Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the latest issue of the peer-reviewed journal, Integrative Cancer Therapies.

19 Jul 2011

Scientists discover cholesterol moves far slower within and between cells

Neutrons have shown the movement of cholesterol between and within cells takes far longer than previously thought. Findings could impact the treatment of a range of diseases linked to abnormal rates of cholesterol transfer.

19 Jul 2011

Thalidomide analog shows promise against sickle cell disease

A thalidomide analog is shaping up as a safe, worthy opponent of sickle cell disease, Georgia Health Sciences University researchers report.

19 Jul 2011

A*Star Institute of Microelectronics shortens drug development cycle with new silicon-based screening tool

Researchers from A*STAR Institute of Microelectronics (IME) have developed a lateral silicon-based drug screening tool that has demonstrated simultaneous capture of 12 individual cells – 12 times higher throughput than conventional patch clamping. The device can be scaled up to allow 1536 cell-recordings simultaneously, permitting 16 times higher throughput than existing planar patch clamp approach.

19 Jul 2011

Researchers identify potential therapeutic target for ER-negative breast cancer

Using a new in vivo screening system, Whitehead Institute researchers have identified a protein in the serine biosynthesis pathway that is essential in estrogen receptor (ER)-negative breast cancer—a notoriously difficult disease to treat associated with low five-year survival rates.

19 Jul 2011

Scientists find way to make copper-catalyzed click chemistry biocompatible

Biomolecular imaging can reveal a great deal of information about the inner workings of cells and one of the most attractive targets for imaging are glycans - sugars that are ubiquitous to living organisms and abundant on cell surfaces. Imaging a glycan requires that it be tagged or labeled. One of the best techniques for doing this is a technique called click chemistry.

19 Jul 2011

Anti-malaria drug provides key insight into potential treatments for autoimmune diseases

In a study published recently in the journal Science Signaling Van Andel Research Institute (VARI) scientists demonstrate on the molecular level how the anti-malaria drug chloroquine represses inflammation, which may provide a blueprint for new strategies for treating inflammation and a multitude of autoimmune diseases such as arthritis, multiple sclerosis, and certain cancers.

19 Jul 2011